$CLBS Caladrius Biosciences, Inc.

CLBS

“Evidence suggests that severe lung damage due to COVID-19 may lead to long-term disability as a result of vascular damage. Although many therapies are targeting the SARS-CoV-2 virus or the reduction of severe inflammation caused by the virus during the acute phase of the illness, no therapy has been shown to repair COVID-19-induced long-term lung […]

SENS – Senseonics Holdings – $SENS

[wp-rss-aggregator feeds=”sens”] Updates: Form SC 13D/A, 3 FEB 2021: http://archive.fast-edgar.com/20210203/AQZ2F222H222KTZ2222W2ZZEJ9QKJ22SB232/ Form 8-K, 26 JAN 2021: http://archive.fast-edgar.com/20210126/A3BZA22C8222JTZZ272H2ZZZ6PVCZ2V2ZB32/ Senseonics Holdings Announces $50.0 Million Bought Deal Offering of Common Stock Senseonics Holdings, Inc. (NYSE American: SENS) (Senseonics or the Company), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) […]

$AXU – Alexco Resource Corporation

$AXU

Alexco Announces $10.5 Million Bought Deal Flow-Through Share Public Offering M2 Communications“ENP Newswire” Alexco Resource Corp. (NYSE American/TSX: AXU) (‘Alexco’ or the ‘Company’) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the ‘Underwriters’) co-led by Cormark Securities Inc. and Cantor Fitzgerald Canada Corporation pursuant to which the […]

$LPCN – Lipocine Prices $25 Million Underwritten Public Offering

LPCN stock

Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock SALT LAKE CITY, Jan. 26, 2021 /PRNewswire/ —Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock, offered at a price of $1.75 to the public. […]